Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | September 2, 2020 | News story | Research and Development |
The COVID-19 news round-up this week focuses on coronavirus treatments, with Celltrion Group announcing that the Korean Ministry of Food and Drug Safety has approved the company’s Investigational New Drug application for a Phase 1 trial for their antiviral antibody treatment candidate, while Genexine’s recent clinical trial investigating how its cytokine therapy treats coronavirus has proven effective.
In other news, thousands of coronavirus cases are thought to have been transmitted within UK hospitals, according to a new study.
1. Genexine’s cytokine drug effective in treating coronavirus patients, new study suggests – Published on 27/08/20
Genexine’s recent clinical trial investigating how its cytokine therapy treats coronavirus has proven effective, according to the company.
2. Oxford University’s COVID-19 vaccine begins Phase 3 trial in the US – Published on 01/09/20
AstraZeneca has started a Phase 3 trial of its experimental coronavirus vaccines in the US, making it the third company to start late-stage trials of a vaccine.
3. Thousands of coronavirus cases recorded in hospital were caught on site, new research suggests – Published on 26/08/20
Thousands of coronavirus cases are thought to have been transmitted within UK hospitals, according to a new study.
4. Korea approves Celltrion’s Phase 1 trial of COVID-19 antiviral antibody treatment – Published on 28/08/20
Celltrion Group has announced that the Korean Ministry of Food and Drug Safety has approved the company’s Investigational New Drug application for a Phase 1 trial for their coronavirus antiviral antibody treatment candidate.
5. Moderna says its COVID-19 vaccine shows promise in elderly patients – Published on 27/08/20
Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial.
